<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>20858403</identifier>
<setSpec>1989-7286</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Calvo González, C</dc:author>
<dc:author>Reche Frutos, J</dc:author>
<dc:author>Valverde Megías, A</dc:author>
<dc:author>Donate López, J</dc:author>
<dc:author>García Feijoo, J</dc:author>
<dc:author>Arriola Villalobos, P</dc:author>
<dc:description xml:lang="en">CLINIC CASE A 25 year old patient with high myopia diagnosed of metachronic choroidal neovascularisation in both eyes secondary to punctate inner choroidopathy leading to visual impairment and metamorphopsia. First eye was treated with four injections of ranibizumab after photodynamic therapy and the second eye only with charge dose of ranibizumab, reaching inactivity with good final visual acuity in both eyes. DISCUSSION Ranibizumab is useful in the treatment of this illness. Prospective studies are needed to investigate the usefulness of a combination with adjuvant therapies such as photodynamic therapy.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2010 Apr </dc:date>
<dc:title xml:lang="es">Ranibizumab (Lucentis®) intravítreo en el tratamiento de membrana neovascular coroidea secundaria a coroidopatía punctata interna.</dc:title>
<dc:title xml:lang="en">[Intravitreal ranibizumab (Lucentis®) in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy].</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
